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INTRODUCTION 
Rapid chemical signaling between neurons and target 
cells is dependent upon the precise control of the 
concentration and duration of neurotransmitters in syn- 
aptic spaces. After transmitter release from activated 
nerve terminals, the principal mechanism involved in the 
rapid clearance from the synapse of the biogenic amine 
and amino acid neurotransmitters is active transport of 
the transmitter back into presynaptic nerve terminals or 
glial surrounding cells by one of a large number of 
specific, pharmacologically distinguishable membrane 
transport proteins (1). High affinity, Na+-dependent up- 
take activities, analogous to the noradrenergic carrier 
first described at peripheral synapses by Axelrod and 
colleagues (2) have been identified in mammalian cen- 
tral nervous system (CNS) nerve terminals for the bio- 
genie amine neurotransmitters including norepinephrine 
(NE), dopamine (DA), and serotonin (5HT) for the ex- 
citatory amino acid neurotransmitters L-glutamate and 
L-aspartate, and for the inhibitory amino acid neuro- 
transmitters r-amino butyric acid (GABA) and glycine 
(3). The primary function of plasma membrane neuro- 
transmitter transporters is to clear the synapse of the 
neurotransmitter between nerve impulses and to re- 
plenish neurotransmitter levels in presynaptic nerve 
terminals. In certain cases, Na+-dependent transport 
processes may also mediate the presynaptic accumu- 
lation of neurotransmitter precursors as well. For ex- 
ample, the rate-limiting step in the biosynthesis of ace- 
tylcholine appears to be Na+dependent choline uptake 
into cholinergic nerve terminals by a hemicholinium- 
sensitive high affinity choline transporter (5). 
Neurotransmitter transporters represent critical tar- 
gets for therapeutic and pathological alterations of syn- 
aptic function. This is particularly apparent with the 
tricyclic antidepressants, amphetamines, and cocaine, 
agents that block biogenic amine transport and produce 
dramatic behavioral changes (6). Abnormalities of neu- 
rotransmitter transport can contribute to neuropathol- 
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ogical processes. For example, blockade and/or rever- 
sal of the high affinity plasma membrane L-glutamate 
transporter during ischemia or anoxia elevates the ex- 
tracellular concentration of L-glutamate to neurotoxic 
levels resulting in nerve cell damage (7). Conversely, 
specific GABA uptake inhibitors are being developed as 
potential anticonvulsant and antianxiety agents (8). The 
ability of synaptic transporters to accumulate certain 
neurotransmitter-like toxins, including N-methyW 
phenylpyridine (MPP+), 6-hydroxydopamine, and 5,6- 
dihydroxytryptamine, suggests a role for these active 
transport proteins in the selective vulnerability of neu- 
rons to exogenous agents (9). Therefore, a detailed 
understanding of the molecular structure, function, and 
regulation of neurotransmitter transporters will: 1) en- 
hance our understanding of synaptic signaling, 2) elu- 
cidate the potential role of transporter defects in neu- 
rologic and psychiatric disorders; and 3) aid in the 
development of novel therapeutic agents. Finally, the 
discovery of novel synaptic transporters may contribute 
to the identification of new synaptic regulatory sub- 
stances. 
TWO DISTINCT GENE FAMILIES ENCODE 
PLASMA MEMBRANE NEUROTRANSMllTER 
TRANSPORTERS 
Neurotransmitter transporters are representative mem- 
bers of a family of proteins that transduce free energy 
stored in an electrochemical gradient into work in the 
form of a concentration gradient. Active transport of 
neurotransmitters across the plasma membrane is 
driven by the transmembrane Na+ gradient generated 
by the plasma membrane Na+/K+ ATPase (reviewed in 
ref. 4). Additional ions are also required for transport of 
many neurotransmitters, including extracellular Cl- and 
intracellular K’. These ion sensitivities reflect cotrans- 
port of the ions with the neurotransmitter during each 
translocation cycle. 
In recent years, molecular cloning studies have re- 
vealed that two distinct gene families code for plasma 
membrane neurotransmitter transporter proteins. 
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These include: 1) the Na+- (and Cl-)-dependent family 
that includes transporters for GABA, NE, DA, 5HT, 
glycine, proline, taurine, betaine, and creatine; and 2) 
the Na+- (and K+)-dependent, but Cl--independent, fam- 
ily of transporters that include transporters for the 
excitatory amino acids L-glutamate and L-aspartate 
(Fig. 1). These two families of plasma membrane trans- 
porters exhibit significant differences in their ionic re- 
quirements and proposed structures which are likely to 
reflect underlying differences in transport mechanisms. 
This review will discuss recent advances in our under- 
standing of the structure, expression, and extent of the 
molecular diversity of these two neurotransmitter trans- 
porter gene families. 
Na+- (and Cl-)-Dependent Neurotransmitter 
Transporters 
The molecular characterization of neurotransmitter 
transporters began with the pioneering work of Kanner 
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Fig. 1. Schematic models depicting the proposed transmem- 
brane topology of the two major families of plasma membrane 
neurotransmitter transporters. Potential N-linked glycosylation 
sites on the presumed extracellular domains are depicted. Due 
to the subjective nature of hydropathy analysis, the model 
proposed for the glutamate transporters is controversial (see 
text). Orphan clones refer to recently described putative trans- 
porters (56, 57) which bear sequence homology to the Na+- 
(and Cl-)-dependent ransporters but exhibit a distinct inferred 
membrane topology. 
and colleagues (10) on the purification and cloning of a 
high affinity Na+- (and Cl-)-dependent GABA trans- 
porter from rat brain (rGAT-1). Subsequently, Amara 
and colleagues (11) isolated a cDNA clone for a cocaine- 
and antidepressant-sensitive human NE transporter 
(hNET) by expression cloning (11). Despite dramatic 
differences in pharmacological sensitivities to sub- 
strates and antagonists, rGAT-1 and hNET possessed 
significant (46%) but dispersed amino acid sequence 
identities and exhibited similar inferred membrane to- 
pographies. No significant amino acid sequence identity 
was observed, however, between these two neuro- 
transmitter transporters and other membrane transport 
proteins whose sequences had been determined, in- 
cluding the mammalian facilitated glucose transporters 
(12) the mammalian Na+/glucose cotransporter (13) 
the prokaryotic Na+dependent cotranspotters (14) or 
the ATP-binding cassette membrane transporters, in- 
cluding the multidrug resistance P-glycoproteins (15) 
and the cystic fibrosis transmembrane conductance 
regulator (16). These results established the presence 
of a distinct gene family of neurotransmitter transport 
proteins and paved the way for the rapid identification 
of additional members of this novel gene family. 
Polymerase chain reaction (PCR) and low stringency 
screening techniques have been used to isolate addi- 
tional members of the emerging family of Na+- (and 
Cl-)-dependent neurotransmitter transporters. Based 
upon amino acid sequence conservation (Fig. 2) these 
cDNAs can be divided into three subfamilies including: 
1) the GABA, betaine, taurine, and creatine transport- 
ers; 2) the biogenic amine (NE, DA, and 5HT) trans- 
porters; and 3) the amino acid (L-proline and glycine) 
transporters. The observation that transporters for sub- 
strates with no known neurotransmitter role, such as 
betaine and creatine, belong to this family of transport- 
ers indicates that this family may subserve a greater 
diversity of physiological functions, and should more 
correctly be referred to as the Na+- (and Cl-)-dependent 
plasma membrane transporter family. 
As depicted in Fig. 1, a tentative structural model for 
the Na+- (and Cl-)-dependent plasma membrane trans- 
porters predicts approximately 12 transmembrane (Y- 
helical domains, cytoplasmic NHP- and COOH-termini, 
and a large, glycosylated, extracellular loop separating 
putative transmembrane domains 3 and 4. This pro- 
posed topographical model remains to be experimen- 
tally verified. Although in each case a single cDNA is 
able to induce high affinity Na+- (and Cl-)-dependent 
transport in a nonneural cell line, the subunit stoichi- 
ometry of the native transporter complex has not been 
determined for any member of this family of membrane 
transport proteins. 
The Subfamily of GABA, Betaine, Taurine, and 
Creatine Transporters 
An exciting result to emerge from the molecular char- 
acterization of neurotransmitter transporters was the 
discovery that multiple transporter subtypes exist for 
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certain neurotransmitters. Thus four distinct GABA 
transporter cDNAs have been described which exhibit 
50-69% amino acid sequence identity but differ in their 
pharmacological properties and tissue expression pat- 
terns (10, 17-l 9,81). Traditionally, GABA transporters 
have been classified as “neuronal” or “glial” based upon 
their sensitivity to nipecotic acid (neuronal) or @alanine 
(glial). In this respect, the first GABA transporter sub- 
type cloned, rGAT-1 (lo), exhibited a pharmacological 
profile consistent with that of a neuronal GABA trans- 
porter. Subsequent in situ hybridization and immuno- 
histochemistry studies have confirmed that GAT-1 is 
widely expressed in neurons throughout the nervous 
system. Interestingly, Clark and colleagues (17) have 
recently described a novel Na+- (and Cl-)-dependent 
GABA transporter, which they called GAT-B, that is 
potently inhibited by /3-alanine. However, lesioning 
studies indicated that GAT-B is expressed by neurons 
within the mammalian brain (17). Thus the previously 
established pharmacological classification of GABA 
transporter subtypes is not supported by recent devel- 
opments in the molecular characterization of GABA 
transporter subtypes. 
At least two other GABA transporter subtypes have 
been identified, designated GAT-2 and GAT3 by Liu 
and colleagues (19) that are expressed in both CNS 
and peripheral tissues including liver and kidney. One 
of these subtypes, GAT3, is developmentally regulated 
in mouse brain (19). Its mRNA is abundant in neonatal 
but not adult brain. The physiological relevance of high 
affinity GABA transport in peripheral tissues such as 
liver and kidney remains to be determined. 
The differential tissue distribution and distinct phar- 
macological properties of the four GABA transporter 
subtypes is consistent with the functional specialization 
of individual GABAergic synapses and/or cell types. 
Thus the potential exists for developing novel pharma- 
cological agents which selectively modulate GABAergic 
neurotransmission at synapses that express a particu- 
lar GABA transporter subtype. The preliminary phar- 
macological characterization of the four cloned GABA 
transporter subtypes represents an important first step 
in this direction (19). 
Kanner and colleagues (20) have begun to identify 
specific amino acid residues which are important for 
the transport activity of rGAT-1. Because GABA is a 
zwitterionic molecule, and at least two Na+, and one 
Cl-, are cotransported with GABA during each trans- 
location cycle, charged and polar amino acids located 
in the transmembrane-spanning domains are likely can- 
didates to be important in substrate recognition and/or 
translocation (reviewed in Ref. 20). Indeed, Pantanowitz 
et al. (20) observed that mutation of an arginine residue 
in transmembrane domain 1 of rGAT-1, that is abso- 
lutely conserved throughout all the members of this 
family (see Fig. 3) abolished transport activity. The 
specificity of this effect was established by the obser- 
vation that mutagenesis of four other highly conserved 
transmembrane “charged” amino acids resulted in mu- 
tant transporters with essentially “wild type” transport 
activity (20). Because the subfamily of biogenic amine 
transporters share this conserved arginine residue (see 
Fig. 3), but the cognate biogenic amine substrates lack 
the negatively charged carboxyl group present in 
GABA, it is unlikely that this arginine residue plays a 
specific role in GABA transport, such as substrate 
recognition. More likely, it may participate in the binding 
of ions such as Cl-, or some other function shared by 
all the members of this family. 
A canine betaine transporter (BGT) has been cloned 
from a Madin-Darby canine kidney (MDCK) cell cDNA 
library by expression cloning in Xenopus oocytes (21). 
BGT exhibits 88% amino acid sequence identity to the 
GABA transporter subtype designated GAT-2 (Fig. 2; 
19,21). Betaine functions as a nonperturbing osmolyte 
in the renal medulla. Indeed, expression of BGT mRNA 
is induced by hypertonicity in cultured MDCK cells (21). 
Interestingly, BGT has a higher affinity for GABA (trans- 
port constant = 93 PM) than for betaine (transport 
constant = 398 PM), however, it is likely that only 
betaine is accumulated to significant levels in the renal 
medulla because plasma levels of betaine (-180 PM) 
far exceed those of GABA (cl PM) (reviewed in ref. 21). 
Northern blot analysis indicated that expression of BGT 
is localized to the kidney medulla; no expression was 
observed in kidney cortex, liver, ileal mucosa, epidi- 
dymis, or brain (21). Thus although they exhibit striking 
amino acid sequence conservation, GAT-2 and BGT 
may not represent species homologs (mouse vs. dog) 
of the same transporter; in contrast to BGT, GAT-2 
expression is readily detectable in mouse brain and 
liver, in addition to kidney (19). 
Complementary DNAs encoding high affinity taurine 
transporters (TauT) have been recently isolated and 
functionally expressed from MDCK cells (22) rat brain 
(23) mouse brain (24) and human thyroid cells (25). 
Sequence similarities between the different clones in- 
dicate that they code for species homologs of the same 
taurine transporter. Like BGT, expression of TauT in 
MDCK cells is regulated by hypertonicity supporting the 
role of taurine as a nonperturbing osmolyte in the renal 
medulla (21). Unlike BGT, however, TauT is widely 
expressed in a number of tissues including brain, liver, 
heart, ileum, and epididymis, in addition to kidney (22- 
25). Taurine (2-aminoethanesulfonic acid) is involved in 
a number of important physiological processes in mam- 
mals. These include: 1) bile acid conjugation in hepa- 
tocytes; 2) modulation of calcium flux and neural excit- 
ability; 3) detoxification; and 4) membrane stabilization 
(26). Taurine deficiency has been associated with retinal 
blindness, abnormalities in immune function, abnormal- 
ities in cardiac function, and reproductive abnormalities 
(26). The availability of TauT cDNA clones may help to 
clarify the physiological role of taurine in tissues such 
as retina and brain. 
Recently, an Na’dependent creatine transporter 
(CreaT) was cloned from rabbit brain and fast-twitch 
skeletal muscle (27). The pharmacological properties of 
CreaT are very similar to the endogenous creatine 
transport activity of COS-7 cells. Northern blot analysis 
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Fig. 2. Amino acid sequence relationships between various members of the Na+- (and Cl-)-dependent plasma membrane transporter 
gene family. The percent amino acid sequence identity between pairs of transporters is presented. As shown in the dendrogram, 
three distinct subfamilies can be resolved based upon amino acid sequence similarities: the subfamily of amino acid (L-proline and 
glycine) transporters; the subfamily of GABA, betaine, taurine, and creatine transporters; and the subfamily of biogenic amine 
transporters. For the various GABA transporter subtypes, to maintain consistency, we refer to the nomenclature of Liu et a/. (19). 
PROT, High affinity rat brain L-proline transporter (51); GLYT-1, rat brain glycine transporter (47) [the sequence of GLYT-2, which 
is identical to GLYT-1 except for the first 15 amino acids (49) is not shown]; GAT-1 (10); GAT-2 (81) same as rat brain GAT-3 
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revealed prominent expression of CreaT mRNA in tis- 
sues known to possess high creatine uptake capacity 
including kidney, heart, muscle, and brain (27). Active 
Na+-dependent uptake of creatine, and its interconver- 
sion with phosphocreatine, catalyzed by creatine ki- 
nase, is critical for ATP homeostasis. Preliminary in situ 
hybridization studies revealed a marked nonuniform 
distribution of CreaT mRNA in rat brain (28). High levels 
of labeling were observed over white matter fiber tracts 
including the corpus callosum and internal capsule, 
specific brain stem nuclei, and the granule cell layer of 
the cerebellum. Interestingly, Blakely and colleagues 
(28) have localized the human CreaT gene at, or near, 
a locus for an inherited juvenile onset CNS disease with 
demyelinating characteristics. The availability of the 
CreaT cDNA will now provide the opportunity to inves- 
tigate the role of this transporter in individual tissues 
including the brain. 
The Subfamily of Biogenic Amine Transporters 
The cloning and functional expression of hNET from an 
SK-N-SH cell line (11) firmly established that a single 
polypeptide contained the binding sites for cocaine and 
antidepressants and induced high affinity NE transport 
in a nonneural cell (11). Sequence analysis of the hNET 
cDNA predicts a protein of 617 amino acids and a 
molecular size of approximately 69 kilodaltons. The 
hydropathy plot of hNET is superimposable with that of 
rGAT-1 indicating that these two proteins exhibit similar 
membrane topographies. 
Northern blot analysis revealed that two distinct tran- 
scripts of 5.8 and 3.6 kilobases (kb) hybridized to the 
hNET cDNA probe under high stringency conditions 
(11). The 5.6-kb message is abundantly expressed in 
SK-N-SH and PC-12 cells and in rat brain stem and 
adrenal gland. In contrast, the 3.6-kb RNA, which is 
likely to arise from the same gene, exhibits a more 
widespread and diffuse distribution (11). Thus the larger 
5.6-kb message is likely to code for the NE transporter 
synthesized in noradrenergic neurons. The role of the 
3.6-kb message remains to be determined. 
The amino acid sequence homology between hNET 
and rGAT-1 provided the means for the isolation of rat 
(29, 30) bovine (31) and human (32, 33) dopamine 
transporters (DATs) and rat (34, 35) and human (36) 
serotonin transporters (SERTs). The biogenic amine 
transporters exhibit 48-67% amino acid sequence iden- 
tity. This high degree of sequence conservation is not 
surprising based upon overlapping pharmacological 
sensitivities of these transporters to substrates and 
antagonists, including the psychostimulant cocaine. In 
situ hybridization studies have localized the expression 
of DAT and SERT to rat brain pathways specific to 
each of the cognate neurotransmitters. In particular, in 
situ hybridization studies using DAT cDNA revealed 
intense hybridization signals overlying the substantia 
nigra zona compacta, ventral tegmental area, periglom- 
erular region of the olfactory bulb, and discrete regions 
of the hypothalamus, brain regions containing numer- 
ous dopaminergic cell bodies (39; Fremeau, Jr., R. T., 
M. G. Caron, and R. D. Blakely, unpublished observa- 
tions). Similarly, SERT mRNA was observed overlying 
the serotonergic cells of the midbrain and brain stem 
Raphe nuclei (34). Interestingly, SERT mRNA was also 
detected in the rat adrenal gland (34). Because 5HT 
has been detected in mast cells lining rat adrenal arte- 
rioles (37) and in a population of adrenal medullary 
cells synthesizing epinephrine (38), these results sup- 
port a physiological role for SERT in the adrenal gland. 
The molecular cloning of hSERT from the human 
placental trophoblastic “JAR” cell line (36) has resolved 
previous discrepancies in the reported sequences of rat 
brain (34) and rat basophilic leukemia (RBL) cell line 
(35) SERTs. It is now clear that the rat brain and RBL 
SERT cDNAs are identical to each other and possess 
92% amino acid identity with the human placental 
SERT. Thus it appears that peripheral and brain sero- 
tonin transporters are identical and arise from the same 
gene, providing further validation for studies of platelet 
serotonin transport activity in human neuropsychiatrlc 
disorders. 
Previous studies suggest that second messengers 
may dynamically regulate the activity of the serotonin 
transporter. Myers and colleagues (40) observed that 
phorbol ester treatment of human pulmonary endothe- 
lial cells resulted in the rapid down-regulation of sero- 
tonin transport. This effect was antagonized by the 
protein kinase C inhibitor staurosporine. Interestingly, 
a comparison of the predicted amino acid sequences 
of the human and rat SERTs (36) revealed several 
conserved consensus sequences for protein kinase- 
mediated protein phosphorylation. Thus future studies 
could examine the role that protein phosphorylation 
plays in the dynamic regulation of serotonin transport 
activity. Cool and colleagues (41) reported that treat- 
ment of placental JAR cells with cholera toxin resulted 
in a robust increase in serotonin transport activity. 
However, the relatively long time course of the effect 
compared to the rapid rise in CAMP levels, is more 
consistent with effects on gene expression or mRNA 
stability, rather than a direct effect on transport activity 
mediated by phosphorylation of the transporter protein. 
This is an important result because it provides a prec- 
edent for humoral modulation of the SERT gene. Such 
a mechanism could underlie the observed reductions in 
platelet and brain serotonin transporter sites and/or 
uptake in major depression, obsessive-cumpulsive dis- 
described in ref. 18; GAT-3, originally called GAT-2 (18); GAT-4, originally designated GAT-6 (17) (GAT-B was the second GABA 
transporter subtype identified, but for consistency of nomenclature we refer to it as GAT-4); BGT, canine betaine transporter (21); 
TauT, canine taurine transporter (22); CreaT, rabbit brain and skeletal muscle creatine transporter (27); NET, human norepinephrine 
transporter (11); DAT, rat brain dopamine transporter (29, 30); SERT, human serotonin transporter (36). 
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Fig. 3. Alignment of predicted amino acid sequences encoding different members of the Na+- (and Cl-)-dependent plasma membrane 
transporter gene family. Boxed residues represent those amino acids absolutely conserved across all the members of this family 
of transporters. Solid lines above PROT reflect the presumed location of the 12 transmembrane domains. For abbreviations see 
Fig. 2. 
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order, or after suicide (reviewed in ref. 36). In this 
respect, it will be of considerable interest to examine 
the effects of circulating steroid hormones on SERT 
gene expression. 
Two interesting features emerged from the pharma- 
cological characterization of the cloned DATs. First, 
hDAT exhibited approximately 6-fold higher potency for 
cocaine compared to rDAT [inhibition constant (Ki) = 
58 nM for hDAT compared to Ki = 320 nM for rDAT] 
(32). In contrast, the potency of cocaine at hNET is Ki 
= 320 nM (11) and at hSERT it is Ki = 610 nM (39). 
Thus, of the cloned human biogenic amine transporters, 
hDAT exhibits the highest affinity for cocaine supporting 
the “dopamine hypothesis” of cocaine reinforcement in 
humans. Second, there is an apparent discrepancy 
between the potency of the Parkinsonism-inducing neu- 
rotoxin, MPP+, to block DA uptake at hDAT or rDAT, 
and its potency to block the endogenous DA transport 
activity of rat striatal synaptosomes (32). Previously, 
Javitch and colleagues (42) observed that MPP’ inhib- 
ited DA transport in rafstriatal synaptosomes with an 
I&, of 170 nM. In contrast, Giros and colleagues (32) 
observed an I&, value of approximately 10 PM for 
MPP+ in Ltk cells stably transfected with hDAT or rDAT. 
These results raise the possibility that cell lines trans- 
fected with DAT are missing a key component required 
for the recognition and/or transport of MPP’ or, less 
likely, that a dopamine transporter subtype with a high 
affinity for MPP’ may exist. Interestingly, Giros and 
colleagues (32) also observed an approximately 1 O-fold 
reduction in affinity of hDAT for DA itself, compared to 
rat striatal synaptosomes. 
The human genes for the biogenic amine transporters 
have been mapped; however, no apparent linkage to 
any established disease gene loci have been observed. 
Human DAT has been mapped to the distal end of 
chromosome 5 (5~15.3) (32, 33); hSERT has been 
mapped to chromosome 17qll.l-17ql2 (39); and 
hNET has been mapped to chromosome 16 (43). 
The molecular cloning of the biogenic amine trans- 
porters provides important new tools for studying the 
biological basis of neuropsychiatric disorders. It should 
now be possible to examine whether defects in biogenic 
amine transporter genes are involved in specific brain 
disorders. In this respect, it is significant that Wright 
and colleagues (44) discovered that a point mutation in 
the Na+/glucose cotransporter gene abolishes its trans- 
port activity resulting in a potentially fatal human dis- 
ease, glucose/galactose malabsorption. The availability 
of biogenic amine transporter cDNAs also provides the 
opportunity to use mutagenesis techniques to examine 
the structural basis of the differential drug sensitivities 
of these important synaptic regulatory proteins. For 
example, sitedirected mutagenesis studies of rDAT are 
beginning to reveal amino acid residues important in 
cocaine binding and DA transport. These results sug- 
gest that like the catecholamine receptors, polar and 
charged residues within the putative transmembrane 
domains of DAT may comprise the substrate recogni- 
tion site. Specifically, mutation of an aspartate residue 
in transmembrane domain 1, which is unique to the 
biogenic amine transporters (Or9 of DAT in Fig. 3) or 
two serine residues in transmembrane 7, disrupted DAT 
transport but differentially altered the binding of a co- 
caine analog (45). Thus it may be possible to dissociate 
amino acid residues required for substrate recognition 
vs. drug binding sites. 
An intriguing study has recently been published dem- 
onstrating a dramatic decline in hDAT mRNA compared 
to tyrosine hydroxylase mRNA in the substantia nigra 
of aging humans (46). Since tyrosine hydroxylase is the 
rate-limiting enzyme in the biosynthesis of DA in dopa- 
minergic neurons, this result implies that there is an 
aging-related selective reduction in DAT gene expres- 
sion in dopaminerigc neurons. Future studies are nec- 
essary to determine the significance of this result. 
The Subfamily of Glycine and Proline Transporters 
Several recent reports describe the cloning and func- 
tional expression of cDNAs that code for glycine trans- 
porters (47-49, 79). Two distinct glycine transporters, 
GLYT-1 and GLYT-2, that are identical except for the 
first 15 amino acid residues, appear to arise from a 
common gene by tissue-specific alternative splicing or 
alternative promotor usage (49). Northern blot analysis 
using oligonucleotide probes specific for each trans- 
porter demonstrated the differential expression of 
GLYT-1 and GLYT-2 in brain and peripheral tissues 
(49). Expression of GLYT-1 is widely distributed in brain 
but not in peripheral tissues. In contrast, GLYT-2 is 
expressed in brain and a number of peripheral tissues 
including spleen, lung, liver, stomach, uterus, and pan- 
creas and in the RBL cell line. Using subtype-specific in 
situ hybridization probes, Borowsky and colleagues (49) 
observed nonoverlapping patterns of expression of 
GLYT-1 and GLYT-2 in rat brain. Expression of GLYT- 
1 was found almost exclusively over white matter fiber 
tracts (implying expression in oligodendrocytes), 
whereas GLYT-2 exhibited a heterogeneous expres- 
sion pattern within gray matter, paralleling the distribu- 
tion of mRNA for the a-1 and P-glycine receptor sub- 
units. Thus, there appears to be a considerably wider 
distribution of glycine transporter mRNAs in brain than 
glycinergic neurons (reviewed in ref. 49). 
Our understanding of the neural function(s) of glycine 
continues to evolve. In addition to its role as an inhibi- 
tory neurotransmitter in the spinal cord, brain stem, and 
retina, and its numerous metabolic functions, recent 
evidence suggests that glycine may also function as a 
neurotransmitter/modulator in more rostra1 brain re- 
gions (49). For example, glycine modulates excitatory 
transmission through a coagonist action at N-methyl-o- 
aspartate receptors (50). Future studies of the physio- 
logical role(s) of the individual GLYT subtypes may 
advance our understanding of the neural roles of gly- 
tine. These studies will also aid in the development of 
novel pharmacological agents with anticonvulsant, sed- 
ative, antiepileptic, and antispastic effects. The unex- 
pected expression of the glycine transporter subtype 
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GLYT-2 in mast cells and macrophages raises the 
possibility that glycine may play an important physiolog- 
ical role in these cells (49). 
L-Proline has been postulated to be a neurotransmit- 
ter or neuromodulator in the mammalian CNS (reviewed 
in ref. 51). Like the well characterized amino acid neu- 
rotransmitters, including the excitatory amino acids, L- 
glutamate and L-aspartate, and the inhibitory amino 
acids GABA and glycine, rat brain synaptosomes and 
brain slices exhibit high affinity, Na+-dependent L-pro- 
line uptake (52). Furthermore, exogenously-loaded ra- 
diolabeled L-proline is released from brain slices in a 
Ca*+-dependent manner after K+-induced depolariza- 
tion (53). Studies to define the role of L-proline in 
discrete pathways in the mammalian CNS have not 
been possible due to the inability to block its biosyn- 
thesis or high affinity transport in nervous tissue. Our 
recent cloning of a high affinity Na+-dependent L-proline 
transporter (rPROT) expressed in subpopulations of 
putative glutamatergic neurons of rat brain provides 
compelling support for a specific role for L-proline in 
excitatory transmission (51). The kinetic and pharma- 
cological properties of rPROT clearly distinguish it from 
the low affinity widely expressed iminoglycine trans- 
porter (Table 1). 
Glutamatergic synapses have been implicated in di- 
verse physiological processes including the acquisition 
of associative learning, synapse formation, and neu- 
roendocrine regulation. Abnormalities of glutamatergic 
neurotransmission have been implicated in the patho- 
physiology of excitotoxic neurological disorders. Thus 
an understanding of the physiological role(s) of the 
L-proline transporter, and its substrate, in specific glu- 
tamatergic neurons could provide novel insights into 
synaptic regulatory mechanisms involved in synaptic 
plasticity and excitotoxic neurological disorders. As a 
prelude to studies of expression of the L-proline trans- 
porter in human neurological disease, we have recently 
isolated cDNAs for the human homolog of this trans- 
porter from a human hippocampal cDNA library. These 
cDNA’s exhibit approximately 92% nucleotide identity, 
and greater than 98% amino acid identity with rPROT 
Table 1. Pharmacological Differences Between Rat Brain 
L-Proline Transporter and Brush Border lmino Transporter 
Apparent inhibition constant 
Compound (PM) 
Rat brair? Brush border’ 
L-Proline 9.7 300 
L-Pipacolate 14 200 
Sarcosine (N-methylglycine) 30 8700 
3,4-Dehydroproline 31 2200 
L-Proline methyl ester >lOO 400 
4-OH-L-Proline >lOO 500 
a Inhibition constant values reflect mean estimates of triplicate 
determinations of uptake inhibition curves, adjusting for sub- 
strate concentration as described by Cheng and Prusoff (70). 
b T,, vaccinia virus transient expression in HeLa cells (54). 
c Rabbit jejunal brush border membrane vesicles (71). 
(54). We have recently determined that expression of 
the human high affinity L-proline transporter (hPROT) is 
brain specific (54). Northern blot analysis revealed a 
prominent approximately 4-kb transcript in human 
brain, while no specific hybridizing species were de- 
tected in human liver, kidney, lung, placenta, skeletal 
muscle, heart, or pancreas. This apparent brain-specific 
expression of hPROT is particularly interesting, be 
cause other members of this family of neurotransmiter 
transporters do not show this degree of brain specific- 
ity. These results further underscore the potential rele- 
vance of the high affinity L-proline transporter in neural 
function. Studies of the expression and/or regulation of 
hPROT may shed light on the pathophysiology of type 
II hyperprolinemia, a genetic disorder characterized by 
elevated cerebrospinal fluid concentrations of L-proline 
and a high incidence of childhood seizures (55). 
Orphan Clones 
Two distinct cDNAs have been described that code for 
predicted proteins that exhibit amino acid sequence 
similarity to the family of Na+- (and Cl-)-dependent 
plasma membrane transporters but that exhibit distinct 
membrane topographies (56, 57). In addition to the 
large glycosylated extracellular loop separating trans- 
membrane 3 and 4, which these transporters share 
with the Na+- (and Cl-)-dependent transporters, they 
also contain a large presumably extracellular glycosy- 
lated loop separating transmembrane domains 7 and 8 
(Fig. 1). This feature also makes these putative trans- 
porters approximately 730 amino acids long, about 10% 
longer than the other members of the Na+- (and Cl-)- 
dependent transporter family. Sequence comparisons 
show that these orphan clones exhibit approximately 
65% amino acid sequence identity to each other, but 
only approximately 35% amino acid sequence identity 
with the other members of the Na+- (and Cl-)-dependent 
transporter family (56, 57). 
Functional expression studies of the orphan clones 
have failed to identify their substrates. However, it is 
unclear whether the putative orphan transporters are 
being improperly expressed or whether the appropriate 
substrates have not yet been identified. The develop- 
ment of epitope-tagged orphan constructs and/or the 
development of specific antibodies directed against the 
predicted orphan proteins should aid in interpretation 
of future expression studies. The apparent brain-spe- 
cific expression of the cognate mRNAs for the orphan 
cDNAs (56,57) indicate that these putative transporters 
may be performing interesting roles in nervous tissue. 
Na+- (and K+)-Dependent Glutamate Transporters 
The active transport of glutamate into neurons and glial 
cells plays a key role in regulating synaptic and extra- 
cellular concentrations of this excitatory neurotransmit- 
ter. Recently, three distinct cDNA clones encoding 
structurally related (49-56% sequence identity) high 
affinity L-glutamate transporters have been described. 
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Storck et al. (58) were the first to describe the cloning 
of a high affinity glutamate/aspartate transporter, which 
they called GLAST-1. During the purification of an en- 
zyme involved in cerebroside biosynthesis they copuri- 
fied a hydrophobic protein of 86 kilodaltons. Using 
synthetic oligonucleotide probes based upon partial 
amino acid sequences of the purified protein, they 
isolated cDNA clones from a rat brain cDNA library. 
Nucleotide sequence analysis revealed significant se- 
quence similarity to prokaryotic proton-dependent glu- 
tamatelaspartate carriers (59). Functional expression 
of the cDNA in Xenopus oocytes induced high affinity 
L-glutamate transport. Subsequently two additional glu- 
tamate transporter cDNAs were described. Pines et a/. 
(60) used antibodies directed against a glutamate trans- 
porter purified from rat brain to isolate a cDNA which 
they called GLT-1. GLT-1 immunoreactivity had previ- 
ously been localized to astrocytic processes by immu- 
nocytochemistty (61). Expression of GLT-1 cDNA in 
HeLa cells induced high affinity glutamate uptake that 
was Na+ (and K+) dependent but Cl- independent. Kanai 
and Hediger (62) isolated a glutamate transporter, 
which they called EAAC-1, from a rabbit intestine cDNA 
library by expression cloning with Xenopus oocytes. 
Figure 1 depicts a tentative structural model of the 
glutamate transporters. Because of the subjective na- 
ture of hydropathy analysis, ambiguities exist in the 
assignment of the number of proposed transmembrane 
domains of the three cloned glutamate transporters (58, 
60, 62). Six transmembrane-spanning domains can be 
identified in the amino-terminal approximately 340 
amino acids of the glutamate transporters, while from 
two to six transmembrane-spanning domains can be 
predicted in the carboxy-terminal amino acids (-340 to 
cat-boxy-terminus). Arriza et a/. (63) have previously 
noted that many of the hydrophobic regions predicted 
by sequence hydropathy analysis within the glutamate 
transporter family are more consistent with b-sheets 
than a-helices. Future studies are necessary to experi- 
mentally establish the membrane topography of the 
glutamate transporters. 
Two of the glutamate transporter subtypes, GLAST- 
1 and GLT-1, are expressed predominantly in brain. 
GLT-1. is widely expressed throughout the CNS in 
astrocytes (60) while GLAST-1 is expressed at high 
levels in Bergmann glial cells in the cerebellum (58). In 
contrast, EAAC-1 is expressed in brain as well as a 
number of peripheral tissues including liver, kidney, and 
intestine (62). Surprisingly, within the brain, EAAC-1 is 
expressed in neurons, with prominent expression in 
glutamatergic hippocampal pyramidal and granule neu- 
rons (60). Future studies of the cellular and subcellular 
localization of the cloned glutamate transporter sub- 
types are necessary to provide insights into potential 
roles that individual subtypes might play in the regula- 
tion of excitatory amino acid neurotransmission. In par- 
ticular, it will be important to establish which glutamate 
transporter subtype(s) is (are) expressed in glutama- 
tergic nerve terminals. 
An Na’-independent, Cl-dependent L-glutamate 
transport activity has been described in rat brain syn- 
aptosomes (64) and glioma cell lines (65). Based upon 
differences in ionic requirements, compared to the 
cloned glutamate transporters, it is likely that this glu- 
tamate transporter belongs to a different family of mem- 
brane transport proteins. Because abnormalities in glu- 
tamate transport have been implicated in excitotoxic 
neurological disorders, it will be important to determine 
the extent of the molecular diversity of the family of 
glutamate transporters and the physiological roles of 
the individual subtypes. 
Previously, a human-expressed sequence tag was 
described that exhibited distant homology to an Esch- 
erichia co/i glutamate/aspartate carrier (66). To explore 
the diversity within the family of glutamate transporters, 
we performed a PCR on human hippocampal poly(A)+ 
RNA using primers corresponding to this sequence. We 
identified a novel PCR product that was used to isolate 
a full-length cDNA clone, which we called SATT, from 
human hippocampus that exhibited significant homol- 
ogy with mammalian glutamate transporters (67). Sur- 
prisingly, despite the sequence relationship with gluta- 
mate transporters, expression of this cDNA clone in 
HeLa cells did not induce glutamate transport but did 
induce Na+-dependent neutral amino acid uptake with 
several properties similar to the Na+-dependent neutral 
amino acid transport activity designated system ASC 
(reviewed in ref. 67). 
A comparison of the amino acid sequence of SATT 
with those of the three cloned mammalian glutamate 
transporters may offer insights into the structure/func- 
tion properties of these structurally related but function- 
ally distinct transporters (Fig. 4). Because SATT does 
not transport glutamate, those amino acid motifs that 
it shares with the glutamate transporters, such as the 
AA(I,V,L)FIAQ motif that is conserved throughout the 
evolutionary diversity of glutamate transporters from 
prokaryotes to mammals, may be involved in common 
functions that these transporters share, such as the 
formation and maintenance of a functional transporter. 
These shared motifs are unlikely to be involved in 
substrate recognition. In contrast, those amino acid 
residues that are conserved in the glutamate transport- 
ers, but absent in SATT, could play a role in substrate 
recognition and/or unique regulatory properties of the 
glutamate transporters. In this respect, a number of 
polar and charged residues are conserved between the 
mammalian glutamate transporters but are substituted 
by amino acids that are either neutral or have an 
opposite charge in SATT (Fig. 4). For example, a con- 
served arginine residue in the glutamate transporters 
(R4,, of GLT-1 in Fig. 4) is replaced by threonine in the 
neutral amino acid carrier SATT. Future site-directed 
mutagenesis studies will examine the possibility that 
these residues play a role in glutamate recognition and/ 
or translocation. Previously it has been demonstrated 
that system ASC can transport anionic amino acids at 
pH less than 6 (68). Future studies will characterize the 
pH dependence of the transport properties of SATT to 
investigate the functional basis for the structural and 
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SAm 
GLASTl 
EAACl 
GLTl 
RQALVL SLSRTQVTY 
KSNGEEPRMGSRMGRFQaGVRKRTLLAKKKVQNITKEEh'KS RNAFVL KMSYRRVKY 
KP----ARKGC--------------------------DSKR NNWLLL NLSTLDKFY 
STEGANNMPKQ----,VEVRMHDSHLSSEEPKHRNLGMR"CD KNLLLS PIHPDVVML 
SAT7 
GLASTl 
EAACI 
GLTl 
w T----------L PVPKETVDSF-LDLARNL 
II ENMYREGKIVQV 
IV DEIDRTGSTPEV LVQACFQQYKT--TREE 
II KQLGFGKKNDEV LVQACFQQIQTVTKKVL 
SAT7 
GUST1 
EAACl 
GLTl 
FPSNLWAAFRTYATDYKW'TQNSSSGNVTHEKIPIGTE LIRFFNSLNEA'IMVLVSh'I G 
FKVPIQANETLLGAVINNVSEAMETLTRIREEMVPVPGS LREFFDSLNEAIMRLVAVI A 
VTASDDTGKNGTEESVAVSENRTKEYRV-VGLY ILVDFFNALSDA'IMKIVQII A 
VAPPSEEANTTKAVISLLNFEAPEETKIVIKKGLEFK ADGGVLQHSERDCHEVSDHD C 
278 
298 
267 
296 
SAlT 
GLASTl 
EAACl 
GLTl 
378 
398 
366 
396 
SAT 
GLASTl 
EAACl 
GLTl 
478 
498 
466 
496 
SAT7 QKATKKGEQE------LAFVKV~IP-NCKSEEET----------SPL~QNPAG--PVASAPELE-SKES---VL 532 
GLASTl RHELKNRDVE------MGNSVIEE-----NPIl(KP----------YQLIAQDN--E--PEKPV~SE-~------ 543 
EAACl KKELEQMDVS----'-SEVNIVNPFALESA~DNE----------DSDTKKSYINGCFAMKSDTISFTQTS---QF 524 
GLTl KSELDTIDSQHiU.lHEDIEMTKTQSVYDDTKNHRESNSNQCVYMHNSWIDECK -.TIAANGKSmWEEEF’WKREK 573 
Fig. 4. Alignment of the predicted amino acid sequences of the Na+- (and K+)-dependent, W-independent plasma membrane 
transporter gene family. SAlT is the human Na+dependent neutral amino acid transporter, which exhibits significant amino acid 
sequence similarity with mammalian plasma membrane glutamate transporters (67). GLASTl is the rat brain glutamate transporter 
described by Storck et a/. (58). EAACl is glutamate transporter isolated by Kanai and Hediger (62) from a rabbit small intestine 
cDNA library. GLTl is the rat brain glutamate transporter isolated by Pines et a/. (60). Boxed residues represent those amino acids 
conserved across all four transporters. 
sequence similarity between SAlT and the mammalian 
Na’lglutamate cotransporters. The extent of the mo- 
lecular diversity of the glutamate transporter family and 
perhaps of a larger Na+- (and K+)dependent, Cl--inde- 
pendent transporter gene family remains to be estab- 
lished. 
Proton-Dependent Synaptic Vesicle Transporters 
Synaptic vesicle neurotransmitter transporters repre- 
sent a third family of membrane transporters crucial for 
chemical transmission at synapses (see ref. 69 for 
review). These carriers transport neurotransmitters 
from the cytoplasm into the synaptic vesicle lumen 
using the energy of a proton gradient; uptake of the 
neurotransmitter into the vesicle is coupled to the ex- 
trusion of a proton into the cytoplasm. At least four 
distinct transport activities have been identified using 
purified synaptic vesicles: one for dopamine, serotonin, 
and norepinephrine, a second for the excitatory amino 
acid glutamate, a third for acetylcholine, and a fourth 
for GABA and glycine (69). Recently, significant prog- 
ress has been made in the molecular characterization 
of synaptic vesicle neurotransmitter transporters. Two 
distinct monoamine vesicle transporters have been 
cloned: a chromaffin granule amine transporter and a 
highly related transporter expressed in catecholamin- 
ergic neurons of the brain stem and midbrain (72, 73). 
Hydropathy analysis of the predicted proteins predicts 
the presence of 12 transmembrane-spanning domains 
and a lumenal loop separating transmembrane domains 
1 and 2. Recently, the uric-1 7 gene from Caenorhabdifis 
elegans has been cloned (74). Uric-17 mutations in C. 
elegans produce deficits in neuromuscular function (re- 
viewed in ref. 74). On the basis of sequence similarity 
to the mammalian vesicular monoamine transporters 
and of localization to synaptic vesicles of cholinergic 
neurons in C. elegans, the uric-1 7 gene product appears 
to encode a vesicular transporter for acetylcholine 
(74). Based upon the amino acid sequence homology 
between the mammalian vesicular monoamine trans- 
potters and the putative C. elegans synaptic vesicle 
acetycholine transporter, the rapid identification of ad- 
ditional synaptic vesicle neurotransmitter transporters 
can be expected. 
FUTURE DIRECTIONS 
The molecular identification of neurotransmitter trans- 
porters should permit a refined analysis of the physio- 
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logical role of neurotransmitter uptake in synaptic trans- 
mission at chemical synapses. Historically, the role that 
neurotransmitter transporters play in the regulation of 
synaptic transmission has been inferred from the dra- 
matic behavioral effects of drugs that block bicgenic 
amine transport. However, the precise influence of neu- 
rotransmitter transport on synaptic efficacy is not 
known and the role of uptake regulation in the modu- 
lation of synaptic strength remains largely speculative. 
Does neurotransmitter reuptake differentially modulate 
synaptic responses at metabotropic vs. ionotropic re- 
ceptors? The development of a cell culture system 
where presynaptic reuptake currents and related post- 
synaptic responses can be studied after Ca2+-evoked 
transmitter release indicates that answers should be 
forthcoming (80). The dramatic progress made in the 
molecular cloning and characterization of neurotrans- 
mitter transporters will provide molecular, genetic, and 
immunological tools with which to explore the synaptic 
role of neurotransmitter transport. Specific transporters 
can now be expressed in isolation and their pharma- 
cological and biophysical (75-77) properties studied. 
Furthermore, it should now be possible to elucidate 
binding sites for psychoactive drugs through chimeric 
transporter and site-directed mutagenesis studies. Spe- 
cific antibodies can be prepared against particular trans- 
porter proteins for immunccytochemical localization of 
the cellular and subcellular distribution of transporters. 
These antibodies should permit studies of the mecha- 
nisms that neurons use to target transporter proteins 
to synapses. An examination of the physiological basis 
for multiple transporter subtypes for a given neurotrans- 
mitter may reveal new levels of synaptic heterogeneity. 
Moreover, the existence of neurotransmitter trans- 
porter subtypes should aid in the development of new 
therapeutic agents with reduced side effect profiles for 
treating neuropsychiatric disorders. The availability of 
transporter cDNAs and genes (78) will also permit an 
examination of the potential role of transporter defects 
in neuropsychiatric disorders. Finally, as the molecular 
diversity of neurotransmitter transporters continues to 
be explored, the discovery of the substrates for novel 
transporters may identify new molecules with synaptic 
regulatory roles. The ability to breed transgenic animals 
in which specific transporter genes have been overex- 
pressed or inactivated by homologous recombination, 
may prove particularly powerful in defining the role of 
novel transporters in the nervous system. 
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